Mirum Pharmaceuticals Closes $120 Million Series A

Company also acquires rights to rare liver disease program from Shire

San Diego – November 21, 2018 – Cooley advised Mirum Pharmaceuticals on its $120 million Series A financing. Partners Jason Kent and Kay Chandler led the Cooley team advising Mirum.

New Enterprise Associates led the round, which also included participation by Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.

The financing will support the development of Mirum’s lead drug candidate, maralixibat, for rare cholestatic liver diseases. In conjunction with the financing, Mirum has entered into an agreement with Shire for the exclusive global rights to develop and market maralixibat, as well as volixibat. Shire will receive an upfront payment, an equity position in Mirum and potential future milestone payments and royalties.

Mirum is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.


Related Contacts
Jason Kent Partner, San Diego
Kay Chandler Partner, San Diego
Terren O'Connor Associate, San Diego
Melinda Foletta Associate, San Diego